---
title: Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials
description: AI-based SP263 PD-L1 scoring showed high agreement with pathologists and comparable predictivity for benefit, suggesting utility for stratifying advanced NSCLC patients for anti-PD-(L)1 therapy.
---

[PathAI Publications ](https://www.pathai.com/publications)

# [Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials](https://www.pathai.com/publications/digital-versus-manual-pd-l1-scoring-in-advanced-non-small-cell-lung-cancer-from-the-impower110-and-impower150-trials)

 Written by [Admin](https://www.pathai.com/publications/author/admin) | Aug 2, 2025 4:00:00 AM

## Abstract

Background 

Treatment selection in patients with advanced non-small cell lung cancer (NSCLC) is based on programmed death-ligand 1 (PD-L1) expression, which is usually scored manually and is subject to intra-/inter-pathologist variability. A PD-L1 clone-agnostic artificial intelligence (AI) model for AI-based measurement of PD-L1 (AIM-PD-L1) was developed and assessed in advanced NSCLC using clinical samples from two Phase 3 trials.

Methods 

IMpower110 evaluated atezolizumab versus chemotherapy in PD-L1-positive metastatic, stage IV, squamous/nonsquamous NSCLC. IMpower150 evaluated atezolizumab, carboplatin and paclitaxel, with/without bevacizumab versus carboplatin, paclitaxel, and bevacizumab in patients with metastatic nonsquamous NSCLC. AIM-PD-L1 was developed and deployed on SP263-stained whole slide images (IMpower110, n=509; IMpower150, n=766) for digital scoring of tumor cell (TC) PD-L1 expression and identification of human interpretable features (HIFs) associated with survival outcomes.

Results 

Overall percentage agreements between scoring methods for TC ≥50% and ≥1% cutoffs were high. Survival analyses were similar for PD-L1 subgroups between scoring methods at both TC cutoffs. A non-significant improvement in survival outcomes was observed in patients treated with atezolizumab-containing regimens and classified positive by digital scoring but missed by manual scoring. Two HIFs in the cancer epithelium—density of all PD-L1–positive TC and immune cells—were nominally associated with overall survival. Many HIFs were identified to be predictive for significantly improved progression-free survival with atezolizumab-containing regimens versus control.

Conclusions 

AIM-PD-L1 digital SP263 PD-L1 scoring is concordant with manual scoring showing similar predictivity for benefit and could potentially be used as a predictive marker for patient stratification and selection for anti-PD-(L)1 therapy.

[View Publication](https://www.jto.org/article/S1556-0864(25)00983-9/abstract)

[View full post](https://www.pathai.com/publications/digital-versus-manual-pd-l1-scoring-in-advanced-non-small-cell-lung-cancer-from-the-impower110-and-impower150-trials)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Admin"
  },
  "dateModified" : "2025-10-09T17:27:07.230Z",
  "datePublished" : "2025-08-02T04:00:00Z",
  "headline" : "Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials",
  "image" : {
    "@type" : "ImageObject",
    "height" : 60,
    "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
    "width" : 60
  },
  "mainEntityOfPage" : "https://www.pathai.com/publications/digital-versus-manual-pd-l1-scoring-in-advanced-non-small-cell-lung-cancer-from-the-impower110-and-impower150-trials",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "PathAI Publications"
  }
}
```